Late-breaking abstracts: IBD highlights
A subcutaneous formulation of infliximab, known as CT-P13 SC, has been developed with a view to offer greater flexibility and convenience for patients.
A subcutaneous formulation of infliximab, known as CT-P13 SC, has been developed with a view to offer greater flexibility and convenience for patients.
In a round-up of randomised controlled studies in IBD at UEG Week 2019 included results from the maintenance phase of the UNIFI study in UC and a phase-3… read more.
Professor Jean-Frédéric Colombel (Icahn School of Medicine at Mount Sinai, New York, USA) opened the symposium with an overview of how treatment targets in UC have evolved from improving… read more.
UEGW 2019, held in Barcelona, Spain, was a very interesting meeting, covering a wide range of hot topics from the world on IBD. The meeting was well-attended with… read more.
Many of the 4,000 delegates at IMW in Boston this year, such as Professor Mohamad Mohty (Paris, France) highlighted the spirit of collaboration, with locals Professor Paul Richardson and Professor Noopur Raje discussing their highlights… read more.
The IASLC WCLC meeting, held in Barcelona this year, covered many interesting topics and reported data from clinical trials relevant to the management of lung cancer. In the… read more.
In a debate about whether autologous stem cell transplant (ASCT) is still right for all transplant eligible MM patients, the panel staked out their positions at the International… read more.
Professor Sagar Lonial (Atlanta, USA) and Professor Philippe Moreau (Nantes, France) discuss whether patients are being cured now and what the future holds.
Article written by Tom Collins. Interview by Esther Drain.
Pomalidomide with bortezomib and dexamethasone is one of the best options for multiple myeloma patients who have relapsed while on lenalidomide, but other data are in the offing that could provide even more options, said Professor Philippe Moreau, head of the haematology department at University Hospital in Nantes, France.
Article written by Tom Collins. Interview by Esther Drain. Meletios Dimopoulos, MD, professor and chairman of clinical therapeutics at the University of Athens and a long-time expert in… read more.
Article written by Tom Collins. Interview by Esther Drain In a debate about whether autologous stem cell transplant (ASCT) is still right for all transplant eligible MM patients,… read more.
Pomalidomide with bortezomib and dexamethasone is one of the best options for multiple myeloma patients who have relapsed while on lenalidomide, but other data are in the offing… read more.